Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Entry into a Material Definitive Agreement
15 Mar 24
8-K
Material Modifications to Rights of Security Holders
26 Feb 24
8-K
Departure of Directors or Certain Officers
22 Feb 24
8-K
Regulation FD Disclosure
12 Feb 24
DEF 14A
Definitive proxy
2 Feb 24
PRE 14A
Preliminary proxy
23 Jan 24
8-K
Entry into a Material Definitive Agreement
17 Jan 24
8-K
Celularity Announces Net Sales and Total Revenue Expectations
9 Jan 24
10-Q
2023 Q3
Quarterly report
2 Jan 24
8-K
Departure of Directors or Certain Officers
29 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 Nov 23
NT 10-Q
Notice of late quarterly filing
14 Nov 23
8-K
Entry into a Material Definitive Agreement
19 Sep 23
8-K
Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors
7 Sep 23
8-K
Celularity Announces Multi-year Research Collaboration Services Agreement with Regeneron
29 Aug 23
8-K
Entry into a Material Definitive Agreement
25 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Departure of Directors or Certain Officers
4 Aug 23
8-K
Celularity Inc. Announces $3 Million Registered Direct Offering
28 Jul 23
424B5
Prospectus supplement for primary offering
28 Jul 23
8-K
Entry into a Material Definitive Agreement
21 Jun 23
8-K
Amendments to Articles of Incorporation or Bylaws
16 Jun 23
EFFECT
Notice of effectiveness
5 Jun 23
424B3
Prospectus supplement
2 Jun 23
8-K
THE NEXT EVOLUTION IN CELLULAR MEDICINE Investor Presentation June 2023
31 May 23
CORRESP
Correspondence with SEC
31 May 23
UPLOAD
Letter from SEC
31 May 23
S-3
Shelf registration
25 May 23
10-Q
2023 Q1
Quarterly report
22 May 23
8-K
Entry into a Material Definitive Agreement
19 May 23
8-K
Entry into a Material Definitive Agreement
16 May 23
NT 10-Q
Notice of late quarterly filing
15 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
DEF 14A
Definitive proxy
1 May 23
8-K
Other Events
27 Apr 23
PRE 14A
Preliminary proxy
21 Apr 23
424B5
Prospectus supplement for primary offering
6 Apr 23
8-K
Celularity Inc. Announces $6 Million Registered Direct Offering
6 Apr 23
Latest ownership filings
4
Kyle Fletcher
16 Apr 24
4
John R Haines
16 Apr 24
4
David C Beers
16 Apr 24
4
Robert J Hariri
16 Apr 24
4
Stephen Brigido
16 Apr 24
4
Kyle Fletcher
19 Mar 24
4
Kok Thay Lim
15 Mar 24
SC 13D/A
Dragasac Ltd
15 Mar 24
4
Robert J Hariri
21 Feb 24
4
Adrian Kilcoyne
21 Feb 24
4
John R Haines
21 Feb 24
4
David C Beers
21 Feb 24
4
Stephen Brigido
21 Feb 24
4
Kyle Fletcher
21 Feb 24
SC 13G/A
UNITED THERAPEUTICS Corp
8 Feb 24
4
Kok Thay Lim
17 Jan 24
SC 13D/A
Dragasac Ltd
17 Jan 24
4
Geoffrey M.D. Ling
16 Oct 23
3
Geoffrey M.D. Ling
16 Oct 23
4
Robert J Hariri
10 Oct 23
SC 13G/A
Sorrento Therapeutics, Inc.
5 Oct 23
4
Change in insider ownership
5 Oct 23
4
Adrian Kilcoyne
19 Jul 23
4/A
Kok Thay Lim
30 Jun 23
SC 13D/A
Dragasac Ltd
22 Jun 23
4
Berhad Genting
22 Jun 23
4
Diane L. Parks
16 Jun 23
4
Dean C Kehler
16 Jun 23
4
Robin L Smith
16 Jun 23
4
Marc Mazur
16 Jun 23
4
ESCHENBACH ANDREW C. VON
16 Jun 23
4
JOHN SCULLEY
16 Jun 23
4
Peter Diamandis
16 Jun 23
4
Kok Thay Lim
16 Jun 23
4
Stephen Brigido
17 Apr 23
4
Kyle Fletcher
17 Apr 23
4
Robert J Hariri
17 Apr 23
4
David C Beers
17 Apr 23
4
John R Haines
17 Apr 23
4
Bradley Glover
17 Apr 23